ClinicalTrials.gg
RecruitingNCT06139627Updated Jul 8, 2026

Evaluation of Geriatric Assessment and Management for Older Adults With Non-small Cell Lung Cancer Receiving Chemotherapy Radiation Therapy

An interventional study of Best Practice and Biospecimen Collection in Lung Non-Small Cell Carcinoma and Stage III Lung Cancer AJCC v8, sponsored by City of Hope Medical Center. Recruiting at 3 sites in United States. Open to participants aged 60 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-08.

Sponsored by City of Hope Medical Center · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Started May 2024; still recruiting 2 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
180
Allocation
Randomized
Ages
60 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 28 studies in Carcinoma, Non-Small-Cell Lung by City of Hope Medical Center — 9 open to participants now, 12 under way, 1 of them phase 3. Carcinoma, Non-Small-Cell Lung · City of Hope Medical Center.

Planned enrollment
8th of 27
180 · median 32
Started
2024
with 2 others
No phase
9 of 28
1 open now
Primary completion
2031-07
later than 11 of 11 live
Registered
24th of 28
by date

Among the 28 studies in Carcinoma, Non-Small-Cell Lung by City of Hope Medical Center, this one is the 8th largest by planned enrollment of the 27 interventional ones that give a count, is one of 3 that started in 2024, is one of 9 with no phase, reaches primary completion later than 11 of the 11 other live ones, and was the 24th registered.

Carcinoma, Non-Small-Cell Lung

7,639 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

9 of the 28 studies in Carcinoma, Non-Small-Cell Lung by City of Hope Medical Center are open now, in 1 country. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Where they have run

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 987 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 60 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies in Carcinoma, Non-Small-Cell Lung by City of Hope Medical Center, or all of them as a file.
02

Study summary

This clinical trial tests how well a geriatric assessment (GA) with GA-directed treatment recommendations, compared to GA with usual care, works in identifying risk factors, reducing chemotherapy radiation toxicity and functional decline, and improving the overall quality of life in older patients with non-small cell lung cancer (NSCLC). Older patients with lung cancer undergoing chemotherapy are at an increased risk of adverse outcomes including treatment toxicity and functional and physical consequences. This makes it very challenging for the physicians to balance the benefits against the risk of chemotherapy in older cancer patients. A geriatric assessment may be useful in identifying risk factors for chemotherapy radiation toxicity. Communicating these geriatric assessment findings and assessment-based recommendations to a patient's treating physicians may help them make more informed decisions about treatment options for patients. Making treatment decisions using GA-based recommendations may reduce adverse events and improve outcomes in patients receiving treatment for NSCLC.

Read the detailed description

PRIMARY OBJECTIVE:

I. To demonstrate if providing a GA summary and recommendations for GA-directed interventions to oncology care teams decreases the proportion of older adults with unresectable, stage III NSCLC who experience any grade 3-5 non-hematologic toxicity from chemotherapy and radiation.

SECONDARY OBJECTIVES:

I. To demonstrate the differences between the intervention versus usual care group among:

Ia. Overall grade 3-5 toxicities; Ib. Patient-reported symptomatic toxicities as measured by Patient Reported Outcomes - Common Terminology Criteria for Adverse Events (PROCTCAE), Patient Reported Outcomes Measurement Information System - 10 (PROMIS-10); Ic. Implementation of GA recommendations; Id. GA outcomes including function (Activities of Daily Living/Instrumental Activities of Daily Living,), physical performance (Short Physical Performance Battery, 2 minute [min] walk, falls), polypharmacy (reduction in medication burden), mood (Geriatric Depression Scale 5/15 and PROMIS Anxiety short form 4a); Ie. Quality of life (European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 [EORTC-QLQ-30]); If. Treatment sequencing (concurrent versus sequential) and completion, hospitalizations/emergency department (ED) rates.

EXPLORATORY OBJECTIVE:

I. To explore microbial diversity and blood components at baseline, and at 6 months from treatment initiation as a potential biomarker of treatment-related toxicity and disease response.

OUTLINE: Patients are randomized to 1 of 2 arms.

ARM I: Patients complete a geriatric assessment. Patients and physicians receive the geriatric assessment summary and assessment-based recommendations, which are provided prior to beginning chemotherapy and radiation, at the midpoint of chemotherapy and radiation treatment, and at the end of treatment. Patients also undergo blood and stool sample collection during screening and on study.

ARM II: Patients complete a geriatric assessment, but information other than clinically significant cognitive impairment and depression is not provided to the oncology teams, per usual care. Patients also undergo blood and stool sample collection during screening and on study.

After completion of study intervention, patients are followed up at 4-6 weeks, 10-14 weeks, and 20-26 weeks after baseline.

03

Conditions studied

  • Lung Non-Small Cell Carcinoma
  • Stage III Lung Cancer AJCC v8
04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ONCOLOGY PHYSICIANS INCLUSION:
  • Oncology physicians must work at the participating site with no plans to leave that site or retire at the time of enrollment into the study
  • PATIENTS INCLUSION:
  • Any patient with unresectable non-small cell lung cancer diagnosis who is 60 years of age or older and must be treated at the participating site
  • Clinical staging without pathological confirmation of nodal disease is allowed
  • Plan to start a new cancer treatment regimen within 4-6 weeks from time of baseline study visit. The treatment regimen is up to the discretion of the treating oncology physician. The regimen must include a chemotherapy drug or other agents that have similar prevalence of toxicity. This can be either concurrent or sequential with radiation therapy
  • Chemotherapy will be defined as cytotoxic drugs; in addition, agents (e.g., monoclonal antibodies and targeted agents) will be allowed. Given the rapidly changing landscape of new drugs for cancer, the study team led by the principal investigator (PI) will update the list accordingly after reviewing the toxicity profile of new therapies
  • Patients who are receiving approved cancer treatment in combination or sequentially with radiation including hypo fractionated radiation (45-60Gy in 15-20 fractions) are eligible
  • Those patients with oligometastatic disease having only one site and one lesion outside of the radiation field will be eligible. Examples include a solitary (met), contralateral lung nodule or an adrenal site
  • A patient may also be enrolled on a treatment trial and participate in this study, if all other inclusion and exclusion criteria are met
  • Able to provide , or if the oncology physician determines the patient to not have decision-making capacity, a patient-designated health care proxy (or authorized representative per institutional policies) must sign consent by the baseline visit
  • Participant or healthcare proxy has adequate understanding of the English language (preferred) because not all GA measures have been validated in other languages. Study team should be contacted for any participants with other preferred languages including Spanish and Mandarin. Inclusion of these participants will depend upon the availability of the translators and their ability to accurately translate the measures as approved by the local Institutional Review Board (IRB)

Exclusion criteria

Exclusion Criteria:

  • PATIENTS EXCLUSION:
  • Have surgery planned within 3 months of approach date. Patients who have previously received surgery are eligible
  • Presence of symptomatic (if more than one) at time of study consent process. Patients with history of treated brain metastases or small indeterminate lesions (\< 1cm) are eligible if they are not symptomatic at the time of study enrollment
  • More than one site: Examples: brain and adrenal, adrenal and liver
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
180 participants (estimated)

Study arms

  • Experimental
    Arm I (GA intervention)

    Patients complete a geriatric assessment. Patients and physicians receive the geriatric assessment summary and assessment-based recommendations, which are provided prior to beginning chemotherapy and radiation, at the midpoint of chemotherapy and radiation treatment, and at the end of treatment. Patients also undergo blood and stool sample collection during screening and on study.

    Procedure: Biospecimen Collection · Other: Communication Intervention · Other: Comprehensive Geriatric Assessment · Other: Electronic Health Record Review · Other: Survey Administration

  • Active comparator
    Arm II (usual care)

    Patients complete a geriatric assessment, but information other than clinically significant cognitive impairment and depression is not provided to the oncology teams, per usual care. Patients also undergo blood and stool sample collection during screening and on study.

    Other: Best Practice · Procedure: Biospecimen Collection · Other: Comprehensive Geriatric Assessment · Other: Electronic Health Record Review · Other: Survey Administration

Interventions

  • OtherBest Practice

    Receive usual care

    Also known as: standard of care, standard therapy

  • ProcedureBiospecimen Collection

    Undergo blood and stool sample collection

    Also known as: Biological Sample Collection, Biospecimen Collected, Specimen Collection

  • OtherCommunication Intervention

    Receive GA assessment summary and assessment-based recommendations

  • OtherComprehensive Geriatric Assessment

    Complete GA

  • OtherElectronic Health Record Review

    Ancillary studies

  • OtherSurvey Administration

    Ancillary studies

06

What researchers measure

Primary outcomes

  1. Incidence of grade 3-5 non-hematologic toxicities

    Will be assessed by National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0 (NCI CTCAE v 5.0) for grade 3-5 non-hematologic toxicities. Chi-square test will be used to compare proportion of patients with grade 3-5 non-hematologic toxicity between two arms at 6 months after treatment initiation.

    Time frame: At 6 months from treatment initiation

Secondary outcomes

  1. Overall grade 3 to 5 toxicities

    Will be assessed by National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0 (NCI CTCAE v 5.0) for grade 3-5 toxicities. Chi-square test will be used to compare proportion of patients with grade 3-5 toxicities between two arms at 6 months after treatment initiation.

    Time frame: At 6 months from treatment initiation

  2. Patient-reported symptomatic toxicities

    Will be assessed by the Patient Reported Outcome version of the Common Terminology Criteria for Adverse Events and Patient Reported Outcomes Measurement Information System (PROMIS)-10. Chi-square test or fisher's exact test will be used to examine the difference between the two arms.

    Time frame: At 6 months from treatment initiation

  3. Function

    Will be assessed by activities of daily living/instrumental activities of daily living. T test Chi-square test or fisher's exact test will be used to examine the difference between the two arms.

    Time frame: At 6 months from treatment initiation

  4. Physical performance -SPPB

    Will be assessed by the short physical performance battery (SPPB) which is scored according to instruction, range from 0 to 12), T test, Chi-square test or fisher's exact test will be used to examine the difference between the two arms.

    Time frame: At 6 months from treatment initiation

  5. Physical performance - 2 minute walking

    Will be assessed by 2 minute walking test (meters). T test, Chi-square test or fisher's exact test will be used to examine the difference between the two arms.

    Time frame: At 6 months from treatment initiation

  6. Physical performance - number of falls

    Will be assessed by number of falls (count number). T test, Chi-square test or fisher's exact test will be used to examine the difference between the two arms.

    Time frame: At 6 months from treatment initiation

  7. Polypharmacy

    Will be assessed by the reduction in medication burden. Chi-square test or fisher's exact test will be used to examine the difference between the two arms.

    Time frame: At 3 months from treatment initiation

  8. Mood - GDS

    Will be assessed by the Geriatric Depression Scale (GDS) 5/15 (scored according to guideline). T test, Chi-square test or fisher's exact test will be used to examine the difference between the two arms.

    Time frame: At 6 months from treatment initiation

  9. Mood - Anxiety

    Will be assessed by PROMIS anxiety (scored according to guideline). T test, Chi-square test or fisher's exact test will be used to examine the difference between the two arms.

    Time frame: At 6 months from treatment initiation

  10. Quality of life

    Will be assessed by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 scored according to guideline. T test, Chi-square test or fisher's exact test will be used to examine the difference between the two arms.

    Time frame: At 6 months from treatment initiation

  11. Treatment completion rates

    Chi-square test or fisher's exact test will be used to examine the difference between the two arms.

    Time frame: At 6 months from treatment initiation

  12. Hospitalizations/emergency department visit rates

    Chi-square test or fisher's exact test will be used to examine the difference between the two arms.

    Time frame: At 6 months from treatment initiation

  13. Incidence of adverse events from durvalumab

    Chi-square test or fisher's exact test will be used to examine the difference between the two arms.

    Time frame: After completion of adjuvant treatment (12 months)

07

Study locations

2 of 3 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2024 (actual). Primary completion is estimated for Jul 2031, 85 months after the start.

Of 345 non-industry interventional studies with no phase under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 97. This study's planned 85 months is above that.

Counting every sponsor, half of 361 studies reached it within 51 months; a quarter within 26 and three quarters within 97.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 5, 2023
First posted
Nov 18, 2023
StartActual
May 21, 2024
Primary completionEst.
Jul 19, 2031
CompletionEst.
Jul 19, 2031
Last update
Jul 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06139627
Responsible party
Sponsor
First posted
Nov 18, 2023
Start date
May 21, 2024
Primary completion
Jul 19, 2031 (estimated)
Completion
Jul 19, 2031 (estimated)
Last update
Jul 8, 2026

Study contacts

Arya Amini
principal investigator · City of Hope Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion